Thanks Huts7 for the update - As I say, keep an eye on the...

Thanks Huts7 for the update - As I say, keep an eye on the comp....

Now this set off a memory flag for me from the distant past...







I dug up some old notes on Invossa specifically. Results overall aren't too bad for them...we have discussed stem cells and PRP a number of times over the years (*gak* - has it been that long?)...

They will need to watch their AE's in the trial cohort. We have seen it can be a bit hit and miss, ie some patients get great results, others not so good with AE's etc. It is quite an individualised treatment from an outcome point of view. We cant discount them totally and no doubt they will refine it over the years or at least have a better understanding of who it might work for and under what conditions. I'm also under the impression that it is still quite expensive. (Circa $6000 per injection)

My other thought on this style of treatment is that it is finally an interarticular injection, this naturally has a higher propensity for possible infection/hypersensitivity within the synovial cavity.



Results: INVOSSA was associated with statistically significant
improvement versus placebo in IKDC total score and individual categories, and in VAS score at week 26, 39, and 52. The WOMAC and KOOS
scores were also improved in INVOSSA group compared with placebo.
Serum CTX-I was significantly lower in the INVOSSA treatment group at
week 39 and 52. Urine CTX-II showed a trend toward improvement in
the INVOSSA treatment group, although the differences were not
meeting statistically significant. MRI assessment showed that patients
treated with INVOSSA showed improved cartilage thickness and subchondral bone area in all knee regions, although not meeting statistical
significance. Most frequent adverse events in the INVOSSA group were
Abstracts / Osteoarthritis and Cartilage 26 (2018) S10eS59 S43
peripheral edema (9%), arthralgia (8%), joint swelling (6%), and injection-site pain (5%)



Ref: https://www.oarsijournal.com/article/S1063-4584(18)30203-6/pdf#:~:text=Conclusions%3A%20INVOSSA%20was%20associated%20with,hold%20potential%20as%20a%20DMOAD.

Thanks to Teddywestside for the original post of the graphic above